Brachytherapy
Volume 6, Issue 4 , Pages 280-285 , October 2007

Rectum dose reduction and individual treatment plan optimization for high-dose-rate prostate brachytherapy

  • Tobias Bölling

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • Corresponding Author InformationCorresponding author. Department of Radiotherapy, Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Str.33, D-48129 Münster, Germany. Tel.: +49-251-83-47384; fax: +49-251-83-47355.
    • ,
  • Christos Moustakis

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Hassan Elsayed

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Stefan-Bodo Müller

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Christoph Weining

      Affiliations

    • Department of Urology, University Hospital of Münster, Germany
    • ,
  • Gabriele Reinartz

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Iris Ernst

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Normann Willich

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany
    • ,
  • Stefan Könemann

      Affiliations

    • Department of Radiotherapy, University Hospital of Münster, Germany

Received 24 March 2007 ,Revised 11 June 2007 ,Accepted 29 June 2007.

References 

  1. Zelefsky MJ, Valicenti RK, Goodman K, et al. Prostate cancer. In:  Perez CA,  Brady LW,  Halperin EC, et al. editor. Principles and practice of radiation oncology. 4th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2004;p. 1730–1733
  2. Pinkawa M, Fischedick K, Treusacher P, et al. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer—a phase II study. Radiother Oncol. 2006;78:41–46
  3. Critz FA, Levinson K, Williams WH, et al. Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology. 1997;49:668–672
  4. Galalae RM, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  5. Kovacs G, Galalae R, Loch T, et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol. 1999;175(Suppl. 2):87–88
  6. Mate TP, Gottesman JE, Hatton J, et al. High dose-rate afterloading 192iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525–533
  7. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157–164
  8. Hsu IC, Cabrera AR, Weinberg V, et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 2005;4:202–206
  9. Mahmoudieh A, Tremblay C, Beaulieu C, et al. Anatomy-based inverse planning dose optimization in HDR prostate implant: A toxicity study. Radiother Oncol. 2005;75:318–324
  10. Ghilezan M, Kestin L, Gustafson G, et al. A comprehensive toxicity analysis of 1232 prostate cancer patients treated with pelvic external beam radiotherapy (EBRT) with high dose rate (HDR) brachytherapy boost, adaptive EBRT (ART), or brachytherapy alone (BT). Int J Radiat Oncol Biol Phys. 2006;66(3, Suppl.):S60
  11. Farrus B, Pons F, Sanchez-Reyes A, et al. Quality assurance of interstitial brachytherapy technique in lip cancer: Comparison of actual performance with the Paris System recommendations. Radiother Oncol. 1996;38:145–151
  12. Gillin MT, Dunning BF, Lawton CA, et al. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy. 2006;5:152–156
  13. Kovács G, Pötter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 2005;74:137–148
  14. ICRU 50 . Prescribing, recording and reporting photon beam therapy. Bethesda, MD: ICRU; 1993;
  15. Hille A, Schmidberger H, Töws N, et al. The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer. A prospective three-dimensional analysis. Strahlenther Onkol. 2005;181:709–716
  16. Gerstner N, Wachter S, Dorner D, et al. Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma. Strahlenther Onkol. 1999;175:232–238
  17. Brossner C, Winterholer A, Roehlich M, et al. Distribution of prostate carcinoma foci within the peripheral zone: Analysis of 8,062 prostate biopsy cores. World J Urol. 2003;21:163–166
  18. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  19. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  20. Hartford AC, Niemierko A, Adams JA, et al. Conformal irradiation of the prostate: Estimating long-term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1996;36:721–730
  21. Stasi M, Munoz F, Fiorino C, et al. Emptying the rectum before treatment delivery limits the variation of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol. 2006;80:363–370

PII: S1538-4721(07)00248-6

doi: 10.1016/j.brachy.2007.06.001

Brachytherapy
Volume 6, Issue 4 , Pages 280-285 , October 2007

Article Tools

* Image Usage & Resolution